Ben has been at Agilent for 3 years managing product portfolios focused on advanced applications of Agilent’s technologies. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer split variants of the Cas9 nuclease. Though he met with little success, it inspired a passion for the technology which he has brought with him to Agilent. Prior to joining Agilent, he worked on several start-up companies focused on software and nanopore-based molecular diagnostics. Ben has a PhD and MBA from Washington University in St. Louis.